These are news releases that are related to our Investor efforts. Releases are listed in chronological order and are archived by year. Sign-up to receive news as it is released using the email and RSS tools below.
- Aug 17, 2015Contract administered by the Biomedical Advanced Research and Development Authority focused on Pfenex's Px563L
Pfenex Inc. (NYSE MKT: PFNX), announced today it has signed a five year, cost plus fixed fee contract valued at up to $143.5 million with the Biomedical Advanced Research and Development Authority...
- Aug 13, 2015
Pfenex Inc. (NYSE MKT: PFNX), a clinical-stage biotechnology company engaged in the development of biosimilar therapeutics, including high value and difficult to manufacture proteins, today...
- Jul 29, 2015
Pfenex Inc. (NYSE MKT: PFNX) announced today that its second quarter 2015 financial results will be released on Thursday, August 13, 2015, before the open of market. At 8:30 am Eastern Time,...
- Jun 16, 2015
Pfenex Inc. (NYSE MKT: PFNX), a clinical-stage biotechnology company engaged in the development of biosimilar therapeutics including high value and difficult to manufacture proteins, announced...
- May 14, 2015
Pfenex Inc. (NYSE MKT: PFNX), a clinical-stage biotechnology company engaged in the development of biosimilar therapeutics, including high value and difficult to manufacture proteins, today...
- May 1, 2015
Pfenex Inc. (NYSE MKT: PFNX), a clinical-stage biotechnology company engaged in the development of biosimilar therapeutics including high value and difficult to manufacture proteins, announced...
- Apr 30, 2015
Pfenex Inc. (NYSE MKT: PFNX) a clinical-stage biotechnology company engaged in the development of biosimilar therapeutics including high value and difficult to manufacture proteins, today...
- Apr 28, 2015
Pfenex Inc. (NYSE MKT: PFNX), a clinical-stage biotechnology company engaged in the development of biosimilar therapeutics and high-value and difficult to manufacture proteins, today announced the...
- Apr 24, 2015
Pfenex Inc. (NYSE MKT: PFNX) a clinical-stage biotechnology company engaged in the development of biosimilar therapeutics including high value and difficult to manufacture proteins, today...
- Mar 23, 2015
Pfenex Inc. (NYSE MKT: PFNX), a clinical-stage biotechnology company engaged in the development of biosimilar therapeutics including high value and difficult to manufacture proteins, announced...
